{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:32:45Z","timestamp":1791613965671,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GenSight Biologics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40259-021-00468-9","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T04:08:58Z","timestamp":1612930138000},"page":"201-214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study"],"prefix":"10.1007","volume":"35","author":[{"given":"Catherine","family":"Vignal-Clermont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Girmens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Audo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saddek Mohand","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Errera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Plaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-5178","authenticated-orcid":false,"given":"Magali","family":"Taiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Alain","family":"Sahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"issue":"4","key":"468_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/WNO.0000000000000570","volume":"37","author":"V Carelli","year":"2017","unstructured":"Carelli V, Carbonelli M, de Coo IF, et al. International consensus statement on the clinical and therapeutic management of leber hereditary optic neuropathy. Neuro-Ophthalmol. 2017;37(4):371\u201381.","journal-title":"Neuro-Ophthalmol."},{"issue":"4884","key":"468_CR2","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1126\/science.3201231","volume":"242","author":"DC Wallace","year":"1988","unstructured":"Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNA mutation associated with Leber\u2019s hereditary optic neuropathy. Science. 1988;242(4884):1427\u201330.","journal-title":"Science"},{"issue":"2","key":"468_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1086\/346066","volume":"72","author":"P Yu-Wai-Man","year":"2003","unstructured":"Yu-Wai-Man P, Griffiths PG, Brown DT, et al. The epidemiology of leber hereditary optic neuropathy in the north east of England. Am J Hum Genet. 2003;72(2):333\u20139.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"468_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00401-016-1625-2","volume":"132","author":"P Yu-Wai-Man","year":"2016","unstructured":"Yu-Wai-Man P, Votruba M, Burt\u00e9 F, et al. A neurodegenerative perspective on mitochondrial optic neuropathies. Acta Neuropathol. 2016;132(6):789\u2013806.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"468_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11940-010-0100-y","volume":"13","author":"A Sadun","year":"2011","unstructured":"Sadun A, La Morgia C, Carelli V. Leber\u2019s hereditary optic neuropathy. Curr Treat Opt Neurol. 2011;13(1):109\u201317.","journal-title":"Curr Treat Opt Neurol."},{"issue":"3","key":"468_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/jmg.39.3.162","volume":"39","author":"P Yu-Wai-Man","year":"2002","unstructured":"Yu-Wai-Man P, Turnbull DM, Chinnery PF. Leber hereditary optic neuropathy. Am J Med Genet. 2002;39(3):162\u20139.","journal-title":"Am J Med Genet"},{"issue":"6","key":"468_CR7","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S0002-9394(14)76784-4","volume":"111","author":"NJ Newman","year":"1991","unstructured":"Newman NJ, Lott MT, Wallace DC. The clinical characteristics of pedigrees of Leber\u2019s hereditary optic neuropathy with the 11778 mutation. Am J Ophthalmol. 1991;111(6):750\u201362.","journal-title":"Am J Ophthalmol"},{"key":"468_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/179412","volume":"2011","author":"RD Koilkonda","year":"2011","unstructured":"Koilkonda RD, Guy J. Leber\u2019s hereditary optic neuropathy-gene therapy. From benchtop to bedside. J Ophthalmol. 2011;2011:1\u201316.","journal-title":"J Ophthalmol."},{"issue":"2","key":"468_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/brain\/118.2.319","volume":"118","author":"P Riordan-Eva","year":"1995","unstructured":"Riordan-Eva P, Sanders MD, Govan GG, et al. The clinical features of Leber\u2019s hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation. Brain. 1995;118(2):319\u201337.","journal-title":"Brain"},{"issue":"3","key":"468_CR10","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0161-6420(96)30665-9","volume":"103","author":"EK Nikoskelainen","year":"1996","unstructured":"Nikoskelainen EK, Huoponen K, Juvonen V, et al. Ophthalmologic findings in Leber hereditary optic neuropathy, with special reference to mtDNA mutations. Ophthalmology. 1996;103(3):504\u201314.","journal-title":"Ophthalmology"},{"issue":"11","key":"468_CR11","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1136\/bjophthalmol-2016-310072","volume":"101","author":"A Majander","year":"2017","unstructured":"Majander A, Bowman R, Poulton J, et al. Childhood-onset Leber hereditary optic neuropathy. Br J Ophthalmol. 2017;101(11):1505\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"468_CR12","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/sj.ejhg.5201828","volume":"15","author":"A Puomila","year":"2007","unstructured":"Puomila A, H\u00e4m\u00e4l\u00e4inen P, Kivioja S, et al. Epidemiology and penetrance of Leber hereditary optic neuropathy in Finland. Eur J Hum Genet. 2007;15(10):1079\u201389.","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"468_CR13","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/archneur.64.6.890","volume":"64","author":"L Spruijt","year":"2007","unstructured":"Spruijt L, Smeets HJ, Hendrickx A, et al. A MELAS-associated ND1 mutation causing Leber hereditary optic neuropathy and spastic dystonia. Arch Neurol. 2007;64(6):890\u20133.","journal-title":"Arch Neurol"},{"issue":"3","key":"468_CR14","first-page":"517","volume":"140","author":"NJ Newman","year":"2005","unstructured":"Newman NJ. Hereditary optic neuropathies: from the mitochondria to the optic nerve. Am J Ophthalmol. 2005;140(3):517\u201323.","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"468_CR15","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/sj.eye.6701591","volume":"18","author":"NJ Newman","year":"2004","unstructured":"Newman NJ, Biousse V. Hereditary optic neuropathies. Eye. 2004;18(11):1144\u201360.","journal-title":"Eye."},{"key":"468_CR16","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1167\/iovs.06-0520","volume":"47","author":"P Barboni","year":"2006","unstructured":"Barboni P, Savini G, Valentino ML, et al. Leber\u2019s hereditary optic neuropathy with childhood onset. Investig Ophthalmol Vis Sci. 2006;47:5303\u20139.","journal-title":"Investig Ophthalmol Vis Sci."},{"issue":"3","key":"468_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/jmg.2007.054270","volume":"46","author":"P Yu-Wai-Man","year":"2009","unstructured":"Yu-Wai-Man P, Griffiths PG, Hudson G, et al. Inherited mitochondrial optic neuropathies. J Med Genet. 2009;46(3):145\u201358.","journal-title":"J Med Genet"},{"key":"468_CR18","doi-asserted-by":"publisher","unstructured":"Newman NJ, Carelli V, Taiel M, et al. Visual outcomes in Leber hereditary optic neuropathy patients with the m.11778GA (MTDN4) mitochondrial DNA mutation. J Neuro-Ophthalmol. 2020. https:\/\/doi.org\/10.1097\/wno.0000000000001045.","DOI":"10.1097\/wno.0000000000001045"},{"key":"468_CR19","unstructured":"EMA. European Public Assessment Report: Raxone. 2015 Jun 25. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/raxone-epar-public-assessment-report_en.pdf."},{"issue":"9","key":"468_CR20","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1093\/brain\/awr170","volume":"134","author":"T Klopstock","year":"2011","unstructured":"Klopstock T, Yu-Wai-Man P, Dimitriadis K, et al. A randomized placebo-controlled trial of idebenone in Leber\u2019s hereditary optic neuropathy. Brain. 2011;134(9):2677\u201386.","journal-title":"Brain"},{"key":"468_CR21","doi-asserted-by":"crossref","unstructured":"Marmor MF, Fulton AB, Holder GE, et al (for the International Society for Clinical Electrophysiology of Vision). ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol. 2009;118:69\u201377.","DOI":"10.1007\/s10633-008-9155-4"},{"key":"468_CR22","doi-asserted-by":"crossref","unstructured":"McCulloch DL, Marmor MF. Brigell MG, et al. ISCEV Standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol. 2015;130:1\u201312.","DOI":"10.1007\/s10633-014-9473-7"},{"key":"468_CR23","doi-asserted-by":"crossref","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 2005;140:509\u2013516.","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"468_CR24","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","volume":"92","author":"RB Nussenblatt","year":"1985","unstructured":"Nussenblatt RB, Palestine AG, Chan CC, et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467\u201371.","journal-title":"Ophthalmology"},{"issue":"4","key":"468_CR25","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1001\/jamaophthalmol.2013.7971","volume":"132","author":"BL Lam","year":"2014","unstructured":"Lam BL, Feuer WJ, Schiffman JC, et al. Trial End points and natural history in patients with G11778A Leber hereditary optic neuropathy: preparation for gene therapy clinical trial. JAMA Ophthalmol. 2014;132(4):428\u201336.","journal-title":"JAMA Ophthalmol."},{"issue":"4","key":"468_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1136\/jmg.31.4.280","volume":"31","author":"RJ Oostra","year":"1994","unstructured":"Oostra RJ, Bolhuis PA, Wijburg FA, et al. Leber\u2019s hereditary optic neuropathy: correlations between mitochondrial genotype and visual outcome. J Med Genet. 1994;31(4):280\u20136.","journal-title":"J Med Genet"},{"issue":"2","key":"468_CR27","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1167\/iovs.13-13365","volume":"55","author":"J Guy","year":"2014","unstructured":"Guy J, Feuer WJ, Porciatti V, et al. Retinal ganglion cell dysfunction in asymptomatic G11778A: Leber hereditary optic neuropathy. Invest Ophthalmol Vis Sci. 2014;55(2):841.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"468_CR28","unstructured":"Hwang 2017. Natural history of conversion of Leber\u2019s hereditary optic neuropathy ophthalmology Volume 124, Number 6, June 2017."},{"issue":"7","key":"468_CR29","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1167\/iovs.08-3166","volume":"50","author":"MA Kirkman","year":"2009","unstructured":"Kirkman MA, Korsten A, Leonhardt M, et al. Quality of life in patients with leber hereditary optic neuropathy. Invest Ophthalmol Vis Sci. 2009;50(7):3112\u20135.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"468_CR30","doi-asserted-by":"crossref","unstructured":"Yu-Wai-Man P, Newman NJ, Carelli V, et al. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. Sci Transl Med. 2020;12:eaaz7423.","DOI":"10.1126\/scitranslmed.aaz7423"},{"key":"468_CR31","doi-asserted-by":"crossref","unstructured":"Zingg B, X.-L. Chou X.-L, Zhang Z.-G, L, et al. AAV-mediated anterograde transsynaptic tagging: Mapping corticocollicular input-defined neural pathways for defense behaviors. Neuron. 2017;93:33\u201347.","DOI":"10.1016\/j.neuron.2016.11.045"},{"issue":"31","key":"468_CR32","doi-asserted-by":"publisher","first-page":"18810","DOI":"10.1073\/pnas.2009425117","volume":"117","author":"ML Cooper","year":"2020","unstructured":"Cooper ML, Pasini S, Lambert WS, et al. Redistribution of metabolic resources through astrocyte networks mitigates neurodegenerative stress. Proc Natl Acad Sci USA. 2020;117(31):18810\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"468_CR33","doi-asserted-by":"publisher","first-page":"e1002569","DOI":"10.1371\/journal.pbio.1002569","volume":"14","author":"E Castaldi","year":"2016","unstructured":"Castaldi E, Cicchini GM, Cinelli L, Biagi L, Rizzo S, Morrone MC. Visual BOLD response in late blind subjects with argus II retinal prosthesis. PLoS Biol. 2016;14(10):e1002569.","journal-title":"PLoS Biol"},{"key":"468_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.12.012","author":"NJ Newman","year":"2020","unstructured":"Newman NJ, Yu-Wai-Man P, Carelli V, et al. Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset. Ophthalmology. 2020;. https:\/\/doi.org\/10.1016\/j.ophtha.2020.12.012.","journal-title":"Ophthalmology"},{"issue":"3","key":"468_CR35","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ophtha.2015.10.025","volume":"123","author":"WJ Feuer","year":"2016","unstructured":"Feuer WJ, Schiffman JC, Davis JL, et al. Gene therapy for leber hereditary optic neuropathy: initial results. Ophthalmology. 2016;123(3):558\u201370.","journal-title":"Ophthalmology"},{"issue":"11","key":"468_CR36","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ophtha.2017.05.016","volume":"124","author":"J Guy","year":"2017","unstructured":"Guy J, Feuer WJ, Davis JL, et al. Gene therapy for Leber hereditary optic neuropathy: low- and medium-dose visual results. Ophthalmology. 2017;124(11):1621\u201334.","journal-title":"Ophthalmology"},{"issue":"8","key":"468_CR37","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.ophtha.2020.02.023","volume":"127","author":"J Yuan","year":"2020","unstructured":"Yuan J, Zhang Y, Liu H, et al. Seven-year follow-up of gene therapy for Leber\u2019s hereditary optic neuropathy. Ophthalmology. 2020;127(8):1125\u20137.","journal-title":"Ophthalmology."},{"key":"468_CR38","doi-asserted-by":"publisher","unstructured":"Liu HL, Yuan JJ, Zhang Y, et al. Factors associated with rapid improvement in visual acuity in patients with Leber\u2019s hereditary optic neuropathy after gene therapy. Acta Ophthalmol. 2020 Feb 24. https:\/\/doi.org\/10.1111\/aos.14379. [Epub ahead of print].","DOI":"10.1111\/aos.14379"},{"issue":"3","key":"468_CR39","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000487485","volume":"60","author":"J Yuan","year":"2018","unstructured":"Yuan J, Zhang Y, Wang L, et al. Visual field variability after gene therapy for Leber\u2019s hereditary optic neuropathy. Ophthalm Res. 2018;60(3):176\u201384.","journal-title":"Ophthalm Res"},{"key":"468_CR40","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ebiom.2016.07.002","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang S, Ma S, Wan X, et al. Long-term outcomes of gene therapy for the treatment of Leber\u2019s hereditary optic neuropathy. EbioMedicine. 2016;10:258\u201368.","journal-title":"EbioMedicine."},{"issue":"4","key":"468_CR41","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/jamaophthalmol.2018.6902","volume":"137","author":"C Bouquet","year":"2019","unstructured":"Bouquet C, Vignal Clermont C, Galy A, et al. Immune response and intraocular inflammation in patients with Leber hereditary optic neuropathy treated with intravitreal injection of recombinant adeno-associated virus 2 carrying the ND4 gene: a secondary analysis of a phase 1\/2 clinical trial. JAMA Ophthalmol. 2019;137(4):399.","journal-title":"JAMA Ophthalmol."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-021-00468-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-021-00468-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-021-00468-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T05:17:26Z","timestamp":1615439846000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-021-00468-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["468"],"URL":"https:\/\/doi.org\/10.1007\/s40259-021-00468-9","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]},"assertion":[{"value":"16 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"GenSight Biologics (Paris, France) fully funded and sponsored the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors participated in the conceptualization, data collection, analysis, interpretation, writing, and critical review of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"I\u00a0Audo is supported by the Agence Nationale de la Recherche within the Programme Investissements d\u2019Avenir, Institut Hospitalo Universitaire FOReSIGHT (ANR-18-IAHU-01), LabEx LIFESENSES (ANR-10-LABX-65), Retina France, UNADEV and Foundation Fighting Blindness. JA Sahel is supported by the Agence Nationale de la Recherche within the Programme Investissements d\u2019Avenir, Institut Hospitalo Universitaire FOReSIGHT [ANR-18-IAHU-01] and LabEx LIFESENSES (ANR-10-LABX-65) and is a co-founder and shareholder of GenSight Biologics and a patent co-author on allotopic transport. C Vignal-Clermont is a consultant for Santhera Pharmaceuticals and GenSight Biologics. D O\u2019Shaughnessy is a consultant for GenSight Biologics. M Taiel is employed by GenSight Biologics. JF Girmens, S Mohand Said, M-H Errera and L Plaine have no conflicts of interest that are directly relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in the REVEAL clinical study involving human participants were in accordance with the ethical standards of the ethics committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the ethics committee \u201cComit\u00e9 de Protection des Personnes Ile de France V\u201d\u00a0(H\u00f4pital Saint Antoine\u2014184 rue du Faubourg Saint Antoine 75012 Paris) on 4 November 2013 and by the French Authorities (ANSM: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9) on 26 December 2013.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent to participate in the study and for their data to be published was obtained from all participants.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and publish"}},{"value":"All data associated with this study are available in the main text.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data and materials availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}